Weight Loss
6 articles
Peptide craze hype faces scientific and practical hurdles
Only 1 in 12 patients prescribed GLP-1 treatment remain on the medication after three years, according to data from Prime Therapeutics .
Boehringer Ingelheim drug slashes liver and belly fat
In Phase 3 trials, Boehringer Ingelheim's experimental obesity drug, survodutide, helped recipients shed up to 17% of their body weight over 76 weeks, crucially preserving muscle mass.
Pfizer's obesity drug shows potential for monthly dosing
Mid-stage study data reveals Pfizer's experimental obesity drug, berobenatide, could achieve significant weight loss with a groundbreaking monthly dosing schedule, a stark contrast to current weekly o
Lilly's oral obesity drug shows promising safety and tolerability
Lilly's experimental oral obesity drug, aleniglipron, helped patients lose up to 12.
Retatrutide's Triple Hormone Action Aims to Revolutionize Obesity Treatment
Patients on the highest dose of retatrutide lost an average of 28% of their body weight over 80 weeks in the latest study, a result mirroring bariatric surgery, according to the South Florida Reporter
New Study Revisits Brain Theory and Neuroscience Concepts
Researchers recently pinpointed that the weight-loss effects of the GLP-1 drug semaglutide hinge on increased levels of a single molecule, cyclic adenosine monophosphate (cAMP), in a specific brain re